News Detail
New Delhi, 2 Jan 2025: The Central Drugs Standard Control Organization (CDSCO) plans to further tighten the screws this year on those making and selling spurious and substandard medicines, a widespread problem in India.
As part of the plan, in addition to t......
View Details
Source : Livemint
CDSCO
drug safety
quality
GMP
good manufacturing practices
Schedule M
Union territories
RBI
MSME
Drugs and Cosmetics Act
Spurious drug
investigation
Not of standard quality
Related News
- Complaints filed with FDA and CMO against Solapur Ayush manufacturer; owner refutes allegations (05-01-2025)
- MP FDA forms joint team with Centre to ensure revised Schedule M compliance in pharma cos (05-01-2025)
- Draft notification for extension of Schedule M published for comments (04-01-2025)
- Illegal medical shop busted in Hyderabad (04-01-2025)
- Rajasthan: Registration of psychiatric hospitals, doctors will be mandatory (04-01-2025)
- TSMC serves notice to Rushcare Hospitals for its alleged association with quacks (04-01-2025)
- Pharma teachers faking profiles at multiple institutions, face being blacklisted (04-01-2025)
- DCA officials seize falsely manufactured Calcium tablets worth Rs 1.5 lakh (04-01-2025)
- Cancer drugs present strongest innovation pipeline in next 5 years: Report (04-01-2025)
- US FDA Releases Draft Guidance on Sampling and Testing of In-Process Materials and Drug Products (04-01-2025)